Completed a Phase 1a clinical trial in healthy subjects and atopic subjects with high IgE levels; Entered Phase 1 trial for subcutaneous formulation in 2016.

XmAb7195 targets IgE with its variable domain, and uses the XmAb immune inhibitor Fc domain to target FcγRIIb, resulting in three distinct mechanism of action for reducing IgE levels. By comparison, the only marketed antibody to control IgE in severe asthma, omalizumab, has only one mechanism of action: blocking IgE receptor binding. It does not clear IgE from the circulation or prevent IgE production.